Efficacy of Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Rhinitis - Levocetirizine with PAR

Institut für Atemwegsforschung GmbH0 个研究点目标入组 60 人开始时间: 2006年11月20日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•- At least 2 year history of perennial allergic rhinitis with pronounced symptoms.
•- Sensitization to D. farinae or D. pteronyssinus proved by a prick test (wheal diameter = 3 mm) or measurement of specific IgE (at least RAST class 2) at most one year ago.
•- On visit 2: Sum of the morning nasal obstruction scores documented in the screening diary is at least 40% of the maximal sum the patient could have attained.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Severe diseases and diseases, conditions or findings which might interfere with the study results, deteriorate due to study participation or require impermissible medication. In particular this includes
•(a) restricted liver or kidney function,
•(b) nasal polyps, severe deviations of the nasal septum, and any other considerable impairments of nasal patency,
•(c) an ear, nose or throat inflammation during the last 2 weeks or any other but allergic form of rhinitis,
•(d) asthma requiring any other treatment than short acting ß-agonists on demand,
•(e) atopic dermatitis with considerable probability to require corticosteroid treatment.
•- Intake of impermissible medication or non observance of the designated washout periods.

发起方

Institut für Atemwegsforschung GmbH